Zacks Investment Research upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a sell rating to a hold rating in a research report released on Thursday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

A number of other research analysts also recently weighed in on TXMD. Jefferies Group assumed coverage on shares of TherapeuticsMD in a research report on Tuesday. They issued a buy rating and a $18.00 target price for the company. Oppenheimer Holdings Inc. assumed coverage on shares of TherapeuticsMD in a research report on Tuesday. They issued an outperform rating and a $12.00 target price for the company.

TherapeuticsMD (NASDAQ:TXMD) opened at 7.15 on Thursday. The firm’s market cap is $1.41 billion. TherapeuticsMD has a 12 month low of $4.39 and a 12 month high of $11.26. The stock’s 50 day moving average is $6.26 and its 200-day moving average is $7.34.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Group LTD increased its position in shares of TherapeuticsMD by 2.9% in the third quarter. BlackRock Group LTD now owns 102,236 shares of the company’s stock worth $695,000 after buying an additional 2,861 shares during the period. Rhumbline Advisers increased its position in shares of TherapeuticsMD by 1.6% in the third quarter. Rhumbline Advisers now owns 159,694 shares of the company’s stock worth $1,088,000 after buying an additional 2,540 shares during the period. BlackRock Fund Advisors increased its position in shares of TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the company’s stock worth $34,455,000 after buying an additional 426,991 shares during the period. BlackRock Inc. increased its position in shares of TherapeuticsMD by 7.1% in the third quarter. BlackRock Inc. now owns 16,303 shares of the company’s stock worth $111,000 after buying an additional 1,080 shares during the period. Finally, BlackRock Investment Management LLC increased its position in shares of TherapeuticsMD by 1.3% in the third quarter. BlackRock Investment Management LLC now owns 569,885 shares of the company’s stock worth $3,881,000 after buying an additional 7,579 shares during the period.

ILLEGAL ACTIVITY WARNING: This article was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/25/therapeuticsmd-inc-txmd-upgraded-to-hold-at-zacks-investment-research.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.